1. Home
  2. AX vs ACAD Comparison

AX vs ACAD Comparison

Compare AX & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Axos Financial Inc.

AX

Axos Financial Inc.

HOLD

Current Price

$89.36

Market Cap

5.4B

Sector

Finance

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

N/A

Current Price

$19.73

Market Cap

4.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AX
ACAD
Founded
1999
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
4.4B
IPO Year
2004
2000

Fundamental Metrics

Financial Performance
Metric
AX
ACAD
Price
$89.36
$19.73
Analyst Decision
Strong Buy
Buy
Analyst Count
7
20
Target Price
★ $117.71
$32.16
AVG Volume (30 Days)
310.7K
★ 1.9M
Earning Date
10-29-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
14.13
★ 69.12
EPS
★ 8.48
0.20
Revenue
$81,254,000.00
★ $726,437,000.00
Revenue This Year
$9.81
$18.82
Revenue Next Year
$10.43
$12.56
P/E Ratio
★ $10.44
$100.10
Revenue Growth
23.51
★ 40.45
52 Week Low
$74.89
$19.57
52 Week High
$105.74
$30.96

Technical Indicators

Market Signals
Indicator
AX
ACAD
Relative Strength Index (RSI) 40.83 16.90
Support Level $85.44 N/A
Resistance Level $100.51 $22.72
Average True Range (ATR) 2.15 0.98
MACD 0.06 -0.58
Stochastic Oscillator 51.26 2.34

Price Performance

Historical Comparison
AX
ACAD

About AX Axos Financial Inc.

Axos Financial Inc is a technology-driven, diversified financial services company. Its client-centric, technology-enabled services model provides secure and scalable banking, clearing and custody, and investment advisory solutions to retail and business customers. The Bank provides consumer and commercial banking products and services through its digital online and mobile banking platforms, low-cost distribution channels and affinity partners. It offers deposit and lending products to customers nationwide including consumer and business checking, savings, etc. Its segments are Banking Business Segment and the Securities Business Segment. Majority of income comes from Banking Business Segment- It distribute its loan products through its retail, correspondent and wholesale channels.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: